Closing
Do other cardiovascular drugs improve cardiovascular events more than other treatments?
Mostly studied in coronary & atherosclerotic disease. Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
A coin flip. So far, one result, not yet repeated.
NoUnsureYes
- Belief
- 0.50 (range 0.25–0.70)
- Trials for
- 1
- Trials against
- 0
- Inconclusive
- 0
Already under way
The evidence so far
- Registered trials
- 10
- With posted results
- 1
- Published papers
- 2
Of 2 decided analyses: 1 favor other cardiovascular drugs, 1 find no difference, 0 favor the comparator.
Papers
- Ivabradine in stable coronary artery disease without clinical heart failure.Trial report · 2014
- Canagliflozin and iron metabolism in the CREDENCE trial.Trial report · 2025
Trials
- PROgnostic Value of Precision Medicine in Patients With Myocardial Infarction and Non-obStructive Coronary artEries: the PROMISE Trial.NCT05122780
- Efficacy and Safety of Chinese Herbal Medicine Wen Xin Granules for the Treatment of Unstable Angina Pectoris With Yang Deficiency and Blood Stasis Syndrome: Study Protocol for a Randomized Controlled TrialNCT04661709
- Evaluation of a POlypill and Colchicine for Risk Reduction in Patients With Established Atherosclerotic Cardiovascular Disease: The EPOCA Randomized Clinical TrialNCT06930885
- Effect of Pioglitazone on Insulin Resistance, Progression of Atherosclerosis and Clinical Course of Coronary Heart DiseaseNCT03011775 · 2 posted results
- Impact of Sodium-glucose Cotransporter Type 2 Inhibitors on the Course of Cardiorenal Syndrome in Acute Decompensation of Chronic Heart FailureNCT04778787
- A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT)NCT03514108
- Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)NCT06280976
- Combination Effects of High-dose Statin and Trimetazidine on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Coronary Artery Bypass SurgeryNCT01857921